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Leukodystrophies are hereditary central white matter disorders caused by
oligodendrocyte dysfunction. Recent clinical trials for some of these devastating
neurological conditions have employed an ex vivo gene therapy approach that showed
improved endpoints because cross-correction of affected myelin-forming cells occurred
following secretion of therapeutic proteins by transduced autologous grafts. However,
direct gene transfer to oligodendrocytes is required for the majority of leukodystrophies
with underlying mutations in genes encoding non-secreted oligodendroglial proteins.
Recombinant adeno-associated viral (AAV) vectors are versatile tools for gene transfer
to the central nervous system (CNS) and proof-of-concept studies in rodents have
shown that the use of cellular promoters is sufficient to target AAV-mediated transgene
expression to glia. The potential of this strategy has not been exploited. The major
caveat of the AAV system is its limited packaging capacity of ∼5 kb, providing the
rationale for identifying small yet selective recombinant promoters. Here, we characterize
the human myelin associated glycoprotein (MAG) promoter for reliable targeting of
AAV-mediated transgene expression to oligodendrocytes in vivo. A homology screen
revealed highly conserved genomic regions among mammalian species upstream of
the transcription start site. Recombinant AAV expression cassettes carrying the cDNA
encoding enhanced green fluorescent protein (GFP) driven by truncated versions of
the recombinant MAG promoter (2.2, 1.5 and 0.3 kb in size) were packaged as cy5
vectors and delivered into the dorsal striatum of mice. At 3 weeks post-injection,
oligodendrocytes, neurons and astrocytes expressing the reporter were quantified by
immunohistochemical staining. Our results revealed that both 2.2 and 1.5 kb MAG
promoters targeted more than 95% of transgene expression to oligodendrocytes.
Even the short 0.3 kb fragment conveyed high oligodendroglial specific transgene
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expression (>90%) in vivo. Moreover, cy5-MAG2.2-GFP delivery to the neonate CNS
resulted in selective GFP expression in oligodendrocytes for at least 8 months. Broadly,
the characterization of the extremely short yet oligodendrocyte-specific human MAG
promoter may facilitate modeling neurological diseases caused by oligodendrocyte
pathology and has translational relevance for leukodystrophy gene therapy.
Keywords: oligodendroglia, leukodystrophy, gene therapy, AAV, white matter disorders, myelin-associated
glycoprotein
INTRODUCTION
Recombinant adeno-associated virus (AAV) is the preferred
vector platform for gene delivery to the central nervous system
(CNS) due to its minimal potential to elicit immune response,
episomal localization of the vector genome and long-term
transgene expression. The major restriction of the system is the
small DNA packaging limit of 4.7 kb (Dong et al., 1996).
The AAV serotype-specific tropism depends on interactions
between viral capsid proteins and specific receptors at the
surface of host cells and transduction is determined by
intracellular processing of AAV virions (Xiao et al., 2012).
Finally, transgene expression is controlled by recruitment
of host cell-derived transcription factors to the recombinant
promoters. Direct AAV-mediated DNA transfer to neurons
has proven beneficial in conditions with a primary defect
in this cell population (Weinberg et al., 2013). In addition,
some leukodystrophies, central white matter disorders caused
by genetic deficiencies in oligodendrocyte proteins, have
been trialled successfully by ex vivo gene therapy acting via
cross-correction of dysfunctional oligodendrocytes by uptake
of graft-derived, secreted transgene products (Cartier et al.,
2009; Biffi et al., 2013). With the exception of Canavan
Disease and its models, neurotropic AAV vectors (Klugmann
et al., 2005a; Leone et al., 2012; Ahmed et al., 2013) and
ex vivo gene therapy approaches are blunt tools for treating
leukodystrophies caused by mutations in genes encoding non-
secreted proteins.
The traditional view that AAV is strictly neurotropic has
been based on observations of specific neuronal transgene
expression driven by viral or hybrid promoters (Fitzsimons et al.,
2002). Preclinical proof-of-concept studies showing successful
modification of the AAV system towards selective transgene
expression in oligodendrocytes used ‘‘neurotropic’’ serotypes but
employed the promoter of the mouse myelin basic protein (Mbp)
gene (Chen et al., 1998; Lawlor et al., 2009; von Jonquieres et al.,
2013). These findings support a promoter-swapping strategy for
oligodendrocyte-targeted transgene expression with AAV gene
delivery.
While the Mbp promoter holds promise for potential clinical
applications, its murine origin, relative big size and poor
specificity following neonatal vector delivery, are potential
caveats (von Jonquieres et al., 2013).
The aim of the present study was to characterize a
human oligodendrocyte-specific promoter suitable for reliable
AAV-mediated transgene expression in vivo. In the CNS,
myelin-associated glycoprotein (MAG) is a pre-myelinating
marker responsible for oligodendroglial recognition of axons
and myelin maintenance (Martini and Schachner, 1997). These
features provided the rationale for investigating the potential of
the MAG gene promoter for directed AAV-mediated transgene
expression in oligodendrocytes. Employing a bioinformatics
approach, we identified a 2.2 kb region upstream of the
putative transcription start site of the human MAG promoter
that comprised two areas that were highly conserved across
mammalian species. We then isolated the genomic DNA
fragments and generated AAV plasmids expressing the enhanced
green fluorescent protein (GFP) reporter under the control
of either the 2.2 kb MAG promoter, or truncated 1.5 and
0.3 kb fragments containing both or just one conserved area,
respectively. All three MAG promoter constructs drove GFP
expression in oligodendrocytes in vitro as well as in vivo
following intrastriatal infusion of the corresponding AAV
vectors to adult mice. Neonatal delivery of the MAG2.2-GFP
vector resulted in highly specific oligodendroglial expression
persisting for at least 8 months. Our data suggest that the novel
recombinantMAG promoter will be instrumental for preclinical
gene function studies and clinical gene therapy alike, that require
long-term and specific AAV-mediated transgene expression in
oligodendrocytes.
MATERIALS AND METHODS
Animals
C57BL/6J mice were group-housed (2–4 cage mates) in a
temperature-controlled room (21–22◦C; 49–55% humidity) with
12 h-light-dark-cycle (lights on 7:00–19:00), where food and
water were available ad libitum. Experiments were approved by
the UNSW Animal Care and Ethics Committee (UNSW ACEC
11/130A and 14/154B).
Bioinformatics
We identified the human MAG gene locus using the UCSC
genome browser1. Based on the March 2006 alignment,
the genomic sequence from Chromosome 19q13.1:
40469878–40496547 (Chr. 19: 35289949–35292134 in the
current GRCh38. p2 assembly) including exons, introns and
a 5 kb upstream putative promoter region of the MAG locus
was assessed for genomic conservation using the Vista browser2
1https://genome.ucsc.edu
2http://pipeline.lbl.gov/cgi-bin/gateway2
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(Thoms et al., 2011). The putative MAG promoter and in
particular regions of >50% interspecies conservation were
screened for transcription factor binding sites known to be
relevant to the oligodendroglial linage using JASPAR3, Wilmer
Bioinformatics4 or the Patch1.0 Software5.
Plasmid Constructs
AAV-GFP plasmids in which reporter gene expression
was controlled by the 1.1 kb cytomegalovirus (CMV)
enhancer/chicken β-actin hybrid (CAG) promoter (pAAV-
CAG-GFP), the human glial fibrillary acidic protein promoter
(pAAV-GFAP-GFP), or the mouse myelin basic protein
promoter (pAAV-Mbp-GFP), were generated as described
previously (von Jonquieres et al., 2013).
The regions 2.2 and 1.5 kb upstream of the MAG
transcriptional start site were PCR amplified from a genomic
DNA template isolated from the human oligodendroglial cell
line MO3.13 using specific primers (MAG_2.2 kb_fwd: cct
cagaaggaaccaacactgccag; MAG_1.5 kb_Fwd: cgactccagctccaac
tagg; MAGrev: gcccccacttgccagcccctcccct). The PCR products
were subcloned into the XhoI and AgeI sites of pAAV-Mbp-
GFP to replace the Mbp promoter, generating pAAV-MAG2.2-
GFP and pAAV-MAG1.5-GFP. For truncation of the MAG
promoter down to 0.3 kb, pAAV-MAG1.5-GFP was subjected
to an Acc65I/Bsu36I restriction digest. Separation of a 1.2 kb
fragment corresponding to the 0.3–1.5 kb distal promoter region
was confirmed by agarose gel electrophoresis. The remaining
5.4 kb fragment containing the AAV-plasmid backbone, the
proximal 0.3 kb MAG promoter and the GFP cDNA was gel-
extracted, blunted by Klenow fill-in and re-ligated to obtain
pAAV-MAG0.3-GFP. The integrity of the recombinant clones
was confirmed by analytical digests and DNA sequencing.
AAV Vector Production
AAV vector packaging was performed as described previously
(Harasta et al., 2015). Briefly, human embryonic kidney
293 (HEK 293) cells were triple-transfected with the AAV-
GFP plasmid, the serotype-specific AAV helper plasmid and
the adenovirus helper plasmid (pF∆6) by standard calcium
phosphate transfection. Chimeric AAV1/2 vectors carrying VP1,
VP2 and VP3 capsid proteins from AAV1 and AAV2 at roughly
equal ratios, were produced as described following quadruple
plasmid transfection (Klugmann et al., 2005b; McClure et al.,
2011). All vectors were harvested 60 h after transfection,
purified using iodixanol (OptiPrepTM, Sigma-Aldrich) gradient
ultracentrifugation and concentrated 3× by refilling with
phosphate-buffered saline containing 1 mM MgCl2 and 2.5 mM
KCl using MicrosepTM Advanced Centrifugal Device 100 K
MWCO concentrators (Pall, Surry Hills, NSW, Australia).
Genomic titres were determined with primers designed toWPRE
(During et al., 2003).
3http://jaspar.genereg.net
4http://bioinfo.wilmer.jhu.edu/PDI/index.html
5http://www.gene-regulation.com/pub/databases.html
AAV Vector Delivery In Vivo
Intraparenchymal delivery of AAV vectors into the striatum
of neonatal or adult mice was performed as described (von
Jonquieres et al., 2013). Briefly, 1 µl of AAV-GFP vector,
adjusted to 2 × 1012 vector genomes (vg)/ml, was injected
into the dorsal striatum. Vector delivery was performed
using a microprocessor-controlled mini-pump (World Precision
Instruments (WPI), Sarasota, FA, USA) with a 34G bevelled
needle (WPI).
Adult mice (2–4 months; both sexes) were anesthetized
with isoflurane (4% induction, then 1% maintenance with O2).
Animals were placed into a stereotaxic frame (Kopf instruments,
Tujunga, CA, USA). One microlitre of AAV-GFP vector was
injected into the striatum (+1.1 mmAP,−1.7 mmML,−3.5 mm
DV from bregma). Vector delivery was performed at a rate of
150 nl/min and the needle was left in place for 5 min prior to
slowly retracting it from the brain.
For neonatal vector delivery (P0), pups (8–24 h after birth)
were cryo-anesthetized and AAV administered as described
(Pilpel et al., 2009). Briefly, pups were immobilized by wrapping
in a paper towel covered with wet-ice for 3–5 min and then
positioned in a custom-made styrofoam mold for vector delivery
(100 nl/s) into the striatum (+2.0 mm AP, −1.5 mm ML,
−2.0 mm DV from lambda) using a hand-held needle (WPI).
The needle was left in place for additional 10 s at the end of
the injection to prevent backflow of virus containing solution.
The pups were then re-warmed on a heating matt and rolled
in the bedding of their pre-warmed home cage before being
returned to the dam.
Cell Culture
HEK 293 cells were cultured in Dulbecco’s Modified Eagle
Medium with 10% fetal calf serum and 1 mM sodium pyruvate
and transfected using the calcium phosphate precipitation
method. The mouse oligodendroglial cell line Oli-neu was
cultured in Sato with 1% horse serum and transfected by
electroporation as described (Krämer et al., 1997; Frühbeis
et al., 2013). Differentiation was induced by daily application
of 1 mM dibutyryl cyclic adenosine monophosphate (dbcAMP).
Cells were seeded at a density of 5 × 104 per 11 mm glass
coverslip and then kept for additional 4 days before fixation
or lysis.
Immunoblotting
Detection of the GFP antigen in HEK 293 and Oli-neu protein
lysates following sodium dodecyl sulfate polyacrylamide gel
electrophoresis and electroblotting was performed as described
(Harasta et al., 2015). Forty eight hours (HEK 293) and 96 h
(Oli-neu) post transfection, protein lysates were extracted and
10 µg of total protein was size separated and immobilized on
a polyvinyl fluoride membrane. Equal loading was confirmed
by staining the membrane with Ponceau S. After washing
and blocking using 5% milk powder, the membranes were
incubated with a rabbit anti-GFP antibody, produced in-
house (von Jonquieres et al., 2013). This was followed by
application of an anti-rabbit horseradish peroxidase-conjugated
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secondary antibody (Dianova, Hamburg, Germany), detection
of the immunoreactivity by the enhanced chemiluminescence
system (BioRad, Gladesville, NSW, Australia) and signal capture
(GelDoc, BioRad, Gladesville, NSW, Australia).
Immunohistochemistry
Mice were fixed by transcardial perfusion with 10% buffered
neutral formalin (Sigma) and 40 µm coronal cryosections
spanning the subcortical striatal nuclei (including globus pallidus
and caudate putamen) were collected after cryoprotection in
30% sucrose. Tissue treatment by antigen retrieval followed
by immunodetection of antigens has been described elsewhere
(von Jonquieres et al., 2014). Sections were treated with a
combination of primary antibodies including rabbit-anti GFP
or mouse anti-GFP (Roche, Switzerland) with either mouse
anti-NeuN (Millipore, MA, USA), mouse anti-glial fibrillary
acidic protein (GFAP; Sigma-Aldrich, MO, USA), or rabbit anti-
aspartoacylase (ASPA; Mersmann et al., 2011). ASPA is a marker
of mature oligodendrocytes. In this population, ASPA positive
cells have been reported to overlap 100 and 93% with the widely
used oligodendrocyte soma markers glutathione S-transferase pi
isoform and CC1, respectively (Kawai et al., 2009). Following
incubation with the appropriate Alexa-conjugated secondary
antibodies (Invitrogen, Carlsbad, CA, USA), sections were
mounted on slides and coverslipped with Mowiol (Calbiochem,
Darmstadt, Germany). Fluorescence was visualized using a Zeiss
Z1 AxioExaminer NLO710 confocal microscope (Carl Zeiss
MicroImaging, Germany).
Quantification of Cell-Type Specific
Transgene Expression
Specificity of AAV-mediated transgene expression was assessed
following our previous work (von Jonquieres et al., 2013).
Neonates (P0), or adult mice (n = 3) injected with AAV were
humanely killed by transcardial perfusion 3 weeks later. Some
neonatally injected mice were examined at 8 months for a
long-term study. The identity of GFP-expressing cells in the
striatum was examined by double-immunofluorescence with
antibodies against GFP and ASPA (oligodendrocytes), NeuN
(neurons), or GFAP (astrocytes) in confocal images at 20×
and 40× magnification. The percentage of GFP-expressing cells
per cell-type was determined by counting at least 50 cells
from each of three non-adjacent sections for a total of at least
150 GFP+ cells using the ‘‘cell counter’’ plugin for ImageJ
version 1.45 k (NIH). GFAP is a marker, generally regarded as
pan-astrocytic. However, recent evidence has shown that GFAP
is heterogeneously expressed in the astroglial compartment with
a bias towards white matter and reactive astrocytes (Cahoy et al.,
2008). Therefore, transduced astrocytes were identified based on
the presence of GFAP and morphological criteria. The latter was
possible as the soluble GFP reporter filled the processes of the
host cells.
Statistics
All graphs and statistical analyses were done with GraphPad
Prism 6 Software (La Jolla, CA, USA). Quantitative measures
were analyzed by one-way or two-way analysis of variance
(ANOVA) as appropriate, followed by Tukey’s post hoc test.
Values are presented as the mean± SEM.
RESULTS
Mbp Promoter-Driven Transgene
Expression in Oligodendrocytes Following
Intracranial Injection of AAV1/2, rh39, rh20
and cy5
We reported previously on the efficacy of chimeric AAV1/2 for
the transfer of anMbp promoter driven GFP expression cassette
to the developing, or adult mouse brain (von Jonquieres et al.,
2013). To expand this gene delivery system towards a potential
clinical setting, we screened the transduction specificity of non-
chimeric AAV vector variants rh20, rh39 and cy5, derived from
non-human primates (Gao et al., 2004). These vectors, expressing
GFP under the control of the Mbp promoter, were injected
into the striatum of adult mice. Chimeric AAV1/2-Mbp-GFP
served as a control (Figure 1). Three weeks later, we determined
the relative numbers of GFP+ cells among oligodendrocytes,
neurons or astrocytes by immunohistochemistry. We found that
AAV1/2 and rh20 resulted in highly preferential oligodendroglial
GFP expression, exceeded by rh39 and cy5. For all other
experiments we focused on cy5 as it is a variant of AAV7 that,
based on its extremely weak immunogenicity, has been proposed
to have a strong potential to be developed as a clinical gene
therapy vector (Gao et al., 2002).
Characterization of the Human MAG
Promoter In Silico
Our in silico search of AAV-compatible promoter regions
of oligodendrocyte-specific genes identified a human MAG
promoter region entailing the sequence from position −2184
to the transcription start site. We located a number of known
transcription factor binding sites of the oligodendrocyte lineage
(Figure 2). The distal segment of this fragment contained binding
sites for both positive and negative transcriptional regulators
such as Yin Yang 1 (YY1) and Inhibitor of DNA Binding 4 (Id4;
Marin-Husstege et al., 2006; He et al., 2007; Zolova and Wight,
2011). We therefore decided to also investigate the proximal
1.5 kb of the long fragment since this fragment was devoid of
these motifs but contained binding sites for myelin cell lineage
factors Oligodendrocyte Transcription Factor 1 (Olig1) and SRY-
Box 10 (Sox10) and an evolutionary highly conserved sequence
(Wang et al., 2014). Finally, we also selected the proximal 300 bp
fragment for further characterization as it contains evolutionary
conserved binding sites for myelin gene regulatory factor (MRF)
and Ring Finger Protein 10 (RNF10), critical activators of
myelination in oligodendrocytes or Schwann cells, respectively
(Hoshikawa et al., 2008; Emery et al., 2009; Bujalka et al., 2013).
Another conserved DNA stretch was located between −1315
to −1176. A comprehensive list of transcription factor binding
motifs in the 2.2 kb upstream sequence of theMAG transcription
start site is summarized in Table 1.
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FIGURE 1 | Mbp promoter selectivity targets transgene expression to oligodendrocytes in the adult brain. (A) The indicated adeno-associated viral (AAV)
vectors (2 × 109 vg) were injected into the striatum of adult mice (n = 3). Representative images showing immunohistochemistry for green fluorescent protein
(GFP; green) and cell type specific markers (red) including ASPA (oligodendrocytes), NeuN (neurons) and GFAP (astrocytes). (B) Quantification of relative GFP
reporter expressing in ASPA+ oligodendrocytes, NeuN+ neurons and GFAP+ astrocytes. Two-way analysis of variance (ANOVA) with Tukey’s post hoc test revealed
differences in oligodendroglial GFP expression between AAV1/2 (78.2 ± 4.4%) and rh39 (91.0 ± 1.5%; p < 0.05) as well as rh20 (78.0 ± 1.7%) and rh39 (p < 0.05).
There was no significant difference between rh39 and cy5 (87.0 ± 5.1%); one-way ANOVA with Tukey’s post hoc test. ∗p < 0.05. Bar: 200 µm.
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FIGURE 2 | Myelin Associated Glycoprotein (MAG) promoter inter-species alignment and AAV expression cassettes. (A) VISTA plot of human sequence
across the MAG locus and its genomic conservation in mouse, rat, dog, horse and marmoset. A close-up of the 2.2 kb upstream promoter region shows two
regions of high conservation, suggestive of functional importance, from −118 to −1 bp and from −1315 to −1176 bp upstream the putative transcription start site.
(B) AAV expression cassettes for GFP reporter expression controlled by the 0.3 kb, 1.5 and 2.2 kb human MAG promoter. Transcription factor binding sites with
relevance to oligodendroglial gene expression are indicated.
TABLE 1 | Position of putative transcription factor binding sites in the recombinant human MAG promoter.
Transcription factor Binding motif Site 1 Site 2 Site 3
∗MRF ctggcac −40 to −33 – –
∗RNF10 acaagggcccctttgtgccc −108 to −92 – –
∗SOX10 acaatg −293 to −287 – –
OLIG1 tcagatg −388 to −381 – –
NKX2.2 acttga −2158 to −2152 – –
SP1 ccccctcccca −91 to −79 −1114 to −1103 −1219 to −1208
YY1 gccatg −1894 to −1888 −1949 to −1943 −2000 to −1994
ASCL1 cagctg −1014 to −1008 −1715 to −1709 –
FOXD3 ttttgtttgttt −2111 to −2099 – –
ID4 cacctg −1656 to −1650 −1737 to −1731 –
Zfp191 ggagggg −735 to −728 – –
Notes: ∗Transcription factor binding sites that have been experimentally validated in the rodent MAG promoter. See text for references.
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Recombinant MAG Promoter Shows
Oligodendroglial Selectivity In Vitro
We isolated three overlapping MAG promoter fragments
stretching from position −2.2, −1.5, or −0.3 kb to the
transcription start site. These fragments were inserted in an
AAV2 expression cassette containing the cDNA encoding GFP
(Figure 2). The recombinant AAV plasmids were then used
for transient transfection of HEK 293 cells and subsequent
immunocytochemistry (not shown) or immunoblot detection of
the GFP reporter (Figure 3A). Low level GFP expression was
detectable following transfection with theMAG promoter-driven
constructs. In contrast, the control plasmids in which reporter
gene transcription was driven by the CAG or Mbp promoter
produced robust GFP expression. The difference between Mbp
and MAG promoter activity in HEK 293 cells suggested better
selectivity of the latter.
In order to substantiate this notion by positive data,
we electroporated Oli-neu cells, an in vitro model of
oligodendrocytes, with the GFP reporters controlled by either
one of the three MAG promoter fragments, the GFAP, Mbp,
FIGURE 3 | MAG promoter selectivity in vitro. (A) GFP Immunoblots of HEK 293 and Oli-neu cells transiently transfected with the indicated plasmids.
(B) Immunofluorescence detection of GFP expression following dbcAMP-induced differentiation of Oli-neu cells transfected with the indicated plasmids. Activity of
the GFAP promoter was restricted to cells with astroglial morphology while the other promoters drove transgene expression in cells exhibiting oligodendrocyte
morphology. Representative results of three independent experiments are shown. Bars: 30 µm.
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or CAG promoter. The cultures were then differentiated to
adopt a mature oligodendrocyte-like phenotype, and finally
assessed by immunoblot or GFP-immunocytochemistry.
Unexpectedly, GFP-expression was below the detection limits
of the immunoblot following transfection with any of the three
MAG promoter-GFP constructs (Figure 3A). As the transfection
efficiency was generally>70% judged by CAG-GFP transfectants
(not shown) this result suggested that our recombinant MAG
promoters were hardly active in the Oli-neu model. However,
at the single cell level MAG-GFP transfection resulted in GFP-
immunoreactivity in Oli-neu with oligodendrocyte morphology
(Figure 3B).
Specificity of MAG Promoter Driven cy5
Vectors in the CNS of Adult Mice
We then investigated the potential of the MAG promoter
for AAV-mediated transgene expression in vivo. All three
AAV-MAG-GFP constructs were packaged into cy5 vectors and
delivered to the dorsal striatum of adult mice. At 3 weeks
following vector injection, when AAV-mediated transgene
expression has peaked to stable levels (Klugmann et al.,
2005a), animals were killed and the brains assessed by
immunohistochemistry to detect GFP in immuno-identified
neurons, oligodendrocytes, and astrocytes. Quantitative analyses
of cy5-MAG2.2-GFP specificity judged by relative numbers of
GFP+ cells revealed a definitive oligodendroglial selectivity of
the long MAG promoter fragment in vivo (Figures 4A,B).
Neurons and astrocytes were almost entirely excluded from
GFP-expression. Most oligodendrocytes in the target area,
identified by ASPA immunoreactivity, expressed the GFP
reporter (Figure 4C). Only a negligible number of neurons were
GFP-positive. Similar results were obtained using cy5-MAG1.5-
GFP (Figure 5) and cy5-MAG0.3-GFP (Figure 6). The use of
the GFAP antibody precluded this sort of analysis for astroglia
FIGURE 4 | The recombinant MAG 2.2 promoter drives oligodendrocyte-specific transgene expression in the central nervous system (CNS).
(A) cy5-MAG2.2-GFP (2 × 109 vg) was injected into the dorsal striatum of adult mice 3 weeks prior to analysis (n = 3). Immunohistochemical staining was performed
for GFP (green) and cell type specific markers (red) including ASPA (oligodendrocytes), NeuN (neurons) and GFAP (astrocytes). Arrowheads indicate representative
cells showing colocalization. (B) Quantification of the results in (A) showed that GFP reporter gene expression was almost completely restricted to oligodendrocytes
(98.4 ± 0.8%). Expression in neurons (0.9 ± 0.9%) and astrocytes (0.7 ± 0.67%) was negligible. (C) Relative quantification of the percentage of GFP expressing cells
in each population revealed that 65.1 ± 4.0% of all oligodendrocytes expressed the GFP transgene while the ratio of GFP expressing neurons was extremely low
(0.3 ± 0.27%); One-way ANOVA with Tukey’s post hoc test. ∗∗∗p < 0.001. Bar: 20 µm.
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FIGURE 5 | The MAG 1.5 promoter restricts GFP transgene expression to oligodendrocytes. (A) cy5-MAG1.5-GFP (2 × 109 vg) was injected into the dorsal
striatum of adult mice 3 weeks prior to analysis (n = 3). Immunohistochemical staining was performed for GFP (green) and cell type specific markers (red) including
ASPA (oligodendrocytes), NeuN (neurons) and GFAP (astrocytes). Arrowheads indicate representative cells showing colocalization. (B) Quantification of the results in
(A) showed that GFP reporter gene expression was almost completely restricted to oligodendrocytes (96.0 ± 0.9%). Expression in neurons (2.8 ± 0.5%) and
astrocytes (1.3 ± 0.6%) was significantly less. (C) Relative quantification of the percentage of GFP expressing cells in each population revealed that 82.6 ± 7.7% of
all oligodendrocytes expressed the GFP transgene while the ratio of GFP expressing neurons was extremely low (0.8 ± 0.1%); One-way ANOVA with Tukey’s
post hoc test. ∗∗∗p < 0.001. Bar: 20 µm.
as it labels heterogeneous astrocyte populations (Cahoy et al.,
2008).
Selectivity of cy5-MAG2.2-GFP in the CNS
of Neonatal Mice
Somatic transgenesis in the mouse, achieved by neonatal vector
administration and transduction of target oligodendrocytes,
holds potential for disease modeling and gene function
studies. In the rodent forebrain, MAG expression starts at P5
(Mingorance et al., 2005) and AAV-mediated gene activation
in the CNS takes several days as it requires uncoating,
nuclear translocation and second-strand synthesis of the
ssAAV genome. Moreover, we have previously reported a
largely superior vector spread following neonatal compared
with adult AAV delivery to the CNS (von Jonquieres et al.,
2013). We therefore investigated the long-term effects of the
MAG promoter in brain sections obtained 8 months after
intracranial AAV-injection to neonates (Figure 7A). We selected
cy5-MAG2.2-GFP for this experiment based on the strict
oligodendroglial selectivity evident from the adult 3 week
expression pattern. GFP in the striatum of animals injected
neonatally was predominantly found in oligodendrocytes, but
also in some neurons and astrocytes (Figure 7B). The number
of GFP+ cells within the oligodendroglial compartments
was limited (Figure 7C). A similar trend was observed in
neonatally infused animals that were analyzed after 3 weeks (not
shown).
Broadly, the performance of the three different MAG
promoter fragments following AAV vector delivery to the
CNS, summarized in Figure 8, was excellent. In the adult
mouse, we observed a remarkably moderate trade-off between
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FIGURE 6 | The truncated MAG0.3 promoter is sufficient to restrict AAV-mediated transgene expression to oligodendrocytes. (A) cy5-MAG0.3-GFP
(2 × 109 vg) was injected into the dorsal striatum of adult mice 3 weeks prior to analysis (n = 3). Immunohistochemical staining was performed for GFP (green) and
cell type specific markers (red) including ASPA (oligodendrocytes), NeuN (neurons) and GFAP (astrocytes). Arrowheads indicate representative cells showing
colocalization. (B) Quantification of the results in (A) showed that GFP reporter gene expression was almost completely restricted to oligodendrocytes (90.7 ± 2.1%).
Expression in neurons (2.5 ± 1.7%) and astrocytes (6.8 ± 2.4%) was significantly less. (C) Relative quantification of the percentage of GFP expressing cells in each
population revealed that 57.3 ± 8.4% of all oligodendrocytes expressed the GFP transgene while the ratio of GFP expressing neurons was extremely low
(0.9 ± 0.6%); One-way ANOVA with Tukey’s post hoc test. ∗∗∗p < 0.001. Bar: 20 µm.
MAG promoter length and oligodendroglial selectivity. Even the
short 0.3 kb fragment greatly limited transgene expression to
oligodendrocytes (Figure 8A). Moreover, the 0.3 kb fragment
also showed activity in the majority of oligodendrocytes in the
target area comparable to the 2.2 kb fragment (Figure 8B).
DISCUSSION
Conventional transgenic mouse lines utilizing myelin gene-
specific promoters have informed on selective cis-acting
elements that were shown to restrict the expression of transgenes
tomyelinating glia. There is virtually no size limitation formyelin
gene promoters used in transgenic mouse lines. In contrast, the
somatic gene delivery system represented by AAV depends on
efficient incorporation of an expression cassette of less than
4.7 kb into the confined space of the viral capsid (Warrington
and Herzog, 2006).
Only a few small cellular promoters have been described
to reliably drive transgene expression in oligodendrocytes
in genetically modified animals. Therefore, the number of
candidates to be adopted for use in viral gene transfer has been
limited. Recently, the 2,3-cyclic nucleotide 3-phosphodiesterase
promoter, first described in transgenic mice (Gravel et al.,
1998), has been reported to convey oligodendroglial-specific
GFP reporter gene expression following lentiviral delivery to the
neonatal mouse brain (Kagiava et al., 2014). Although this 4 kb
promoter fragment is useful in the lentiviral setting harboring
vector genomes up to 8.5 kb, it does not match the AAV size
criteria.
To date, the only cellular promoter used for AAV-
mediated transgene expression in oligodendrocytes is the murine
1.9 kb Mbp cis-regulating element and a truncated version
spanning the proximal 1.3 kb upstream region including parts
of Mbp exon 1 (Chen et al., 1998; Lawlor et al., 2009;
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FIGURE 7 | Long-term expression in oligodendrocytes following neonatal cy5-MAG2.2-GFP delivery. (A) cy5-MAG2.2-GFP (2 × 109 vg) was injected into
the dorsal striatum of neonatal mice (n = 4). At 8 months, immunohistochemical staining was performed for GFP (green) and cell type specific markers (red) including
ASPA (oligodendrocytes), NeuN (neurons) and GFAP (astrocytes). Arrowheads indicate representative cells showing colocalization. (B) Quantification of the results in
(A) showed that GFP reporter gene expression was enriched in the oligodendroglial compartment (82.2 ± 0.4%). Expression in neurons (10.3 ± 1.4%) and
astrocytes (7.6 ± 1.4%) was significantly less. (C) Relative quantification of the percentage of GFP expressing cells in each population revealed that 32.8 ± 2.8% of
all oligodendrocytes expressed the GFP transgene while the ratio of GFP expressing neurons was extremely low (1.0 ± 0.1%). ∗∗∗p < 0.001. Bar: 20 µm.
von Jonquieres et al., 2013). The Mbp promoters have been
used independently to achieve reporter gene expression in the
adult rodent CNS using AAV2, AAV8, rh39, rh20 and cy5
(Chen et al., 1998; Lawlor et al., 2009). Like the 2,3-cyclic
nucleotide 3-phosphodiesterase promoter both Mbp promoters
were selected as they had been shown to drive transgenes in
the oligodendrocyte lineage in transgenic mouse lines generated
by pronucleus injections (Gow et al., 1992; Orian et al.,
1994).
To date there is no oligodendrocyte-specific alternative to the
1.3 and 1.9 kbMbp promoter variants appropriate for AAV viral
gene delivery. The goal of this investigation was to delineate a
novel recombinant promoter suited for clinical gene therapy of
white matter disorders. To that end, we have selected a 2.2 kb
region upstream of the transcription start site in the humanMAG
gene and two truncated variants, that harbor an abundance of
binding motifs for transcription factors known to regulate gene
activity and myelination in oligodendrocytes or Schwann cells
(Emery, 2010).
All three recombinant MAG promoters showed very little
activity in HEK 293 cells despite good transfection efficacy
confirmed to be greater than 80% in CAG-GFP samples.
Compared with the CAG promoter, the 1.9 kb Mbp promoter
showed weaker yet robust GFP expression in HEK 293 cells. We
have, however, identified Oli-neu cells as a suitable model for
qualitative observations on glial promoter selectivity given that
differentiated cultures contain cells with either oligodendrocyte
or astroglial morphology that were permissive forMAG or GFAP
promoter driven GFP expression, respectively.
Our previous data using the Mbp promoter were obtained
using a chimeric AAV vector system that inherently lacks
translational relevance due to the heterogeneity of viral particles
consisting of a wide range of ratios between AAV1 and AAV2
capsid proteins (von Jonquieres et al., 2013). Therefore, the
Frontiers in Molecular Neuroscience | www.frontiersin.org 11 February 2016 | Volume 9 | Article 13
von Jonquieres et al. MAG-Promoter for AAV Gene Therapy
FIGURE 8 | Comparison of MAG promoter-controlled selectivity of AAV-mediated transgene expression. (A) The proportion of oligodendrocytes, neurons
and astrocytes was calculated for each MAG promoter variant in adult AAV injected mice and for cy5-Mag2.2-GFP delivered to neonates. Statistically significant
differences in AAV-mediated oligodendrocyte-specific GFP reporter gene expression were detected between the MAG2.2 and the MAG0.3 promoter following AAV
delivery to adult mice (P < 0.05). In all cases AAV mediated delivery of any of the three MAG-GFP expression constructs resulted in slight but significantly better
restriction of transgene expression to oligodendrocytes than neonatal delivery of MAG2.2-GFP (p < 0.01). (B) Summery of the percentage of GFP+ cells relative to
the population of oligodendrocytes and neurons in the target area. Irrespective of the time point of AAV-delivery the MAG promoter robustly targeted the
oligodendrocyte population. Adult cy5 mediated delivery of any of the three MAG-GFP expression constructs targeted the oligodendrocyte population significantly
more efficiently than cy5-MAG2.2-GFP following neonatal delivery. Two-way ANOVA with Tukey’s post hoc test. ∗p < 0.05; ∗∗p < 0.01; ∗∗∗p < 0.001.
current study employed the AAV7-derived variant cy5 as a
candidate for clinical gene therapy applications since neutralizing
antibodies to AAV7 are rare in human serum (Gao et al., 2002).
While a recent pioneering study has confirmed very good vector
spread following cy5-CAG-GFP delivery to the adult rodent
brain the effects of cellular promoters were not examined (Lawlor
et al., 2009).
We have shown previously that the vector spread depends
on the developmental stage of the target tissue at the time
of infusion but not on the cellular promoter used in the
expression cassette (von Jonquieres et al., 2013). Thus, our
current investigations focused on promoter selectivity rather
than vector spread. We have previously reported that the Mbp
promoter exhibits mostly astroglial activity following injection at
P0. As this developmental stage in the mouse CNS corresponds
to the second prenatal trimester in humans (Clancy et al., 2001),
it is of limited clinical relevance. However, somatic transgenesis
in the mouse, achieved by vector delivery at P0, is instrumental
for disease modeling (Dayton et al., 2012). Therefore, we
selected cy5-MAG2.2-GFP for intracranial injection at P0 and
noticed GFP expression mostly in oligodendrocytes for at least
8 months.
Although a comparison between the transduction profiles of
the vectors carrying the MAG promoter (this study) and the
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Mbp promoter (von Jonquieres et al., 2013) is not feasible, it
appears that in neonates the MAG promoter might be better
suited for transgene expression targeted to oligodendrocytes
(90%) than the Mbp promoter (25%). We hypothesized that
the potential gene delivery to oligodendrocyte precursor cells
(OPCs) available at P0, a time point preceding MAG expression,
would prime the transduced cells for MAG promoter-driven
transgene expression at later stages as the recombinant AAV-
genome stably remains in the host cell nucleus. However, we
observed only a moderate total number of GFP-expressing
oligodendrocytes following neonatal injections which might
reflect a poor initial transduction efficiency of OPCs and
limited available AAV particles when oligodendrocytes are
born.
To our best knowledge, this is the first report on a MAG
cis-acting element to drive transgene expression in vivo. The
identification of the potential of the 0.3 kb MAG promoter
fragment might be the most important result of the present
study. The significance of this result is outstanding as this
promoter fragment allows incorporation in the genome of self-
complementary (sc) AAV vectors that inherently possess only
half the packaging capacity yet have a superior transduction
profile compared with single-stranded vectors (McCarty, 2008).
Although not investigated here, the presence of a RNF10
site within all three MAG promoter fragments might enable
transgene expression in Schwann cells. This would be an
improvement over the Mbp promoter that lacks the Schwann
cell-specific enhancers required for activity in the peripheral
nervous system (Mathis et al., 2000).
In conclusion, the MAG promoter has superior features
considering its human origin, small size and oligodendroglial
selectivity in adults and neonates. Combined with its potential
to sustain long-term transgene expression, the recombinant
MAG promoter represents a valuable addition to the AAV
toolbox.
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